
EU Greenlights Merck’s KEYTRUDA® Combo for High-Risk NSCLC Treatment
Merck, also known as MSD outside of the United States and Canada, has announced today that the European Commission (EC) has granted approval for KEYTRUDA, Merck’s anti-PD-1 therapy. This approval allows its use in combination with platinum-containing chemotherapy as neoadjuvant…